Chemical formula: C₂₂H₂₄BrFN₄O₂ Molecular mass: 475.354 g/mol PubChem compound: 3081361
Vandetanib is indicated for:
Population group: only adults (18 years old or older)
Vandetanib is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
Vandetanib is indicated in adults, children and adolescents aged 5 years and older.
For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Vandetanib is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
Vandetanib is indicated in adults, children and adolescents aged 5 years and older.
For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Vandetanib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
